Use the map below to learn more about how Dolon can provide strategic market access support for your product or rare disease portfolio throughout all stages of development.
Use the map below to learn more about how Dolon can provide strategic market access support for your product or rare disease portfolio throughout all stages of development.
Click a marker
to view more info
In order to demonstrate the value of a new medicine, it’s important to first understand the existing disease landscape. In rare diseases, natural history is often poorly documented and treatment pathways can be highly variable.
Dolon can help you gain insight into the following issues to lay the foundation for the development of your product’s value story:
What is the burden of disease in the target indication for your product?
What are the existing treatment options and their reimbursement status?
What is the unmet need?
Dolon understands how payers assess the value of new treatments for rare diseases. Taking into account the target profile for your product, we provide strategic guidance on how to position your product to show maximum value by considering:
What are the key differentiators for your product and how will payers perceive their value?
How should your product be positioned in the context of current disease management?
What evidence will you need to support this positioning?
Achieving successful market access for a new rare disease treatment requires coordination and integration of evidence, strategy and messaging, often in an iterative fashion.
Dolon can help you identify and prioritise critical activities to support market access, taking into account timing and dependencies between tasks, the need for cross-functional alignment and geographical considerations such as the impact of international reference pricing on launch sequencing.
Drawing on Dolon’s experience and knowledge of how payers assess new treatments for rare diseases, we can help train staff in the local affiliates to roll out your product value proposition.
We can provide training on how to deliver clear, consistent messaging, maximise the use of payer communication tools, anticipate payer challenges and guide you towards the evidence to respond to these challenges.
At Dolon, we not only have up-to-date knowledge to advise you on the latest developments in rare disease policy, but we also think it’s important to play a role in shaping that policy. We undertake research to understand the impact of pricing & reimbursement policies on access to orphan drugs and to support policy development to ensure new life-saving treatments continue to be available.
Dolon understands that manufacturers, patients, prescribers, payers and policy makers all come from different perspectives, but they also have a common goal of ensuring access for patients with rare and severe diseases to life-saving treatments. We have a track record of bringing together stakeholders from different sides of the table to discuss, engage, debate and ultimately seek common ground in determining policies that will support investment and access to treatments for rare diseases in the future.
Case Study
Interactive & educative pricing exercise
Early in the product lifecycle, assumptions about the anticipated price and achievable reimbursement level for your product can help inform the clinical development programme and market access strategy. Dolon can build models to forecast revenue under different scenarios and assumptions to help inform key decisions such as the choice of trial comparator and endpoints, launch sequencing by geography or even go / no go decisions about further investment.
Case Study
Bespoke analytics & financial planning tools
Pricing of rare disease medicines can be both controversial and complex. Dolon combines research, analytics and in-depth knowledge of reimbursement systems to develop a defensible pricing strategy that reflects the value of your product. The impact of price on both market access and revenue can be tested through simulations under different assumptions and scenarios.
Case Study
Ultra-orphan drug pricing strategy
A strong value proposition needs to be supported by robust evidence. Phase III trials should be designed not only to satisfy regulatory requirements, but also to demonstrate value to payers. However, given the challenges of conducting large-scale studies in rare diseases, it is often necessary to collect additional data beyond randomised controlled trials.
Dolon can help you critically assess the gaps in the evidence base for your product and recommend strategies to fill these gaps.
Communicating the value of your product is as much about the medium as the message itself. Dolon can create a range of tools that integrate messages alongside evidence to prepare you for your next payer interaction, be it an elevator pitch, an objection handling script or an interactive budget impact model for your iPad.
Payers and other decision makers want to understand the budgetary implications of reimbursing new treatments for rare diseases. Dolon has extensive experience in developing budget impact models of varying levels of complexity to suit a wide range of needs. We can even turn you model into an interactive app for use in the field.
At Dolon, we know how to communicate with payers in a way that they will understand. Crafting a compelling value story for rare disease treatments requires the ability to distill complex information into simple, effective messages. Dolon can help you develop, align and test value messages with both internal and external stakeholders.
Case Study
Value messaging & launch support
Developing a market access strategy for a product with multiple indications requires an assessment of the implications of new or future indications on the existing price and value messages for your product.
Dolon can help you integrate these considerations under different scenarios to devise the optimal value strategy for your product in the long run.
Legend ▼▲
Report / slide deckEvidence / literature reviewPublicationAdvisory boardInterviews / surveyInteractive appModelWorkshop / training